A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.

Key facts

Study ID

NCT00639002

Run by

Incyte Corporation

People needed

13

Starts

2008-03-01

Expected to finish

2010-07-01

Last updated by the study team

2018-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of multiple myeloma with evidence of measurable disease.
• Relapsed or refractory disease with at least one line of prior therapy.
• Adequate bone marrow reserve.

You may not qualify if…

• Received anti-cancer medications or investigational therapy in the past 28 days.
• Intracranial disease or epidural disease.

Where it is running

• Study site — Highland, California, United States
• Study site — Boynton Beach, Florida, United States
• Study site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.